FGF23 and X-linked hypophosphatemia: This result is consistent with previous findings in which, despite optimal treatment with oral phosphate and vitamin D analogs, 25–40% of patients with well-controlled XLH still had slow gains in linear growth [18], suggesting that inhibition of excess FGF23 may be pivotal in normalizing skeletal growth and improving bone metabolism [36].